Pluristem Therapeutics has received approval from the Paul-Ehrlich-Institute, Germany's health authority, to provide cells from its advanced, fully automated, and proprietary 3D cell expansion manufacturing platform implemented at its new GMP facility. The company's new manufacturing facility has the capability to efficiently produce more than 150,000 doses of PLX cells per annum. This step represents the first regulatory approval of the company's new facility, where the company has implemented its large scale 3D bioreactor expansion of placental-derived mesenchymal-like Adherent Stromal Cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.02 USD | +6.93% |
|
+4.15% | +29.85% |
07-02 | Pluri Appoints Liat Zalts as CFO | MT |
07-02 | Pluri Inc. Announces CFO Changes, Effective September 30, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+29.85% | 32.44M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluristem Therapeutics, Inc. Receives Approval for 3D Cell Expansion Manufacturing Platform